Post-Vaccination Symptomatic SARS-CoV-2 Infections are Minimal and Non-Serious: An Observational Multicenter Indian Cohort Study of 28342 Healthcare Workers
Preprint
- 1 January 2021
- preprint
- Published by Elsevier BV in SSRN Electronic Journal
Abstract
Background: The healthcare workers (HCWs) have been on the frontline in combating the pandemic and were prioritized for vaccination when COVID-19 vaccines became available. Although vaccines effectively prevent infection in most cases, some cases of post-vaccination infections have been reported, raising concerns about vaccine efficacy. This study investigated the efficacy of COVID-19 vaccines in preventing and reducing the severity of post-vaccination infections (PVI) among HCWs. Methods: This observational study examined 28342 vaccinated HCWs with SARS-CoV-2 (symptomatic severe acute respiratory syndrome coronavirus 2) infections during the initial five months of vaccination (January 16-June 15, 2021). They worked at 43 Apollo Group hospitals in 24 Indian cities. PVI was investigated after recombinant ChAdOx nCOV-19 (Recombinant) or the whole virion inactivated Vero cell vaccines were administered. Various parameters were evaluated such as age, sex, time to infection, type of vaccine, infections after a single and two doses, monthly and regional case distribution, clinical severity of infection, hospitalization and intensive care unit (ICU) requirement, and death. Findings: Symptomatic PVIs occurred in a low percentage of vaccinated cohorts (5⸱07%, p<0⸱001), and these were predominantly mild and did not result in hospitalization, ICU admissions (p<0⸱0001), or death. Both vaccines provided similar protection, with PVI incidences of 5⸱11% and 4⸱58%, following ChAdOx nCOV-19 (Recombinant) and the whole virion inactivated Vero cell vaccines, respectively (p50 years significantly contracted more infections(p<0⸱001 and p=0⸱001, respectively). Two-dose vaccination has significantly lower odds of developing PVI (0.83, 95%CI – 0.72 to 0.97). Maximum infections occurred during the peak of the second COVID-19 wave from mid-April to May 2021 (p<0⸱001). No significant difference existed in the infection between sex, vaccine type, and the number of vaccine doses received (p≥0⸱05). Interpretation: PVI occurred in a small percentage of HCWs. Vaccination protected them significantly from the infection but also severe disease. Funding Information: None. Declaration of Interests: None. Ethics Approval Statement: This study was approved by an Ethical Institutional Committee (EIC), and a consent waiver was given by the EIC.This publication has 17 references indexed in Scilit:
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in CaliforniaThe New England Journal of Medicine, 2021
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination SettingThe New England Journal of Medicine, 2021
- Covid-19: Italy makes vaccination mandatory for healthcare workersPublished by BMJ ,2021
- COVID-19 Vaccines vs Variants—Determining How Much Immunity Is EnoughJAMA, 2021
- Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021Eurosurveillance, 2021
- Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their householdsPublished by Cold Spring Harbor Laboratory ,2021
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipientsThe Lancet, 2021
- Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020Published by Cold Spring Harbor Laboratory ,2021
- A CASE OF VIBRIO CHOLERAE MENINGITIS IN A NEONATEInternational Journal of Advanced Research, 2020
- Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in ChinaClinical Infectious Diseases, 2020